Published on December 2, 2009 at 5:14 AM
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche. T-emerge 1 (subcutaneous weekly taspoglutide versus placebo in treatment-naïve patients) and T-emerge 4 (subcutaneous weekly taspoglutide versus sitagliptin versus placebo) both met their respective primary endpoints of change in HbA1c. In both studies taspoglutide was generally well tolerated. The most frequently reported adverse events among taspoglutide treated patients were nausea and vomiting.
This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation. GLP-1 analogues, which stimulate insulin secretion and suppress glucagon secretion, are true innovations in the diabetes field.
SOURCE Ipsen
36e39dfc-8cd6-4c46-ab1a-3ecd3cb27290|1|2.0
Posted in: Drug Trial News | Medical Condition News
Tags: Blindness, Blood Sugar, Diabetes, Diabetes Mellitus, Endocrinology, Exenatide, Hormone, Insulin, Insulin Glargine, Life Expectancy, Metformin, Nausea, Neurology, Neuropathy, Oncology, Pioglitazone, Placebo, Renal Failure, Stroke, Type 2 Diabetes, Vomiting